This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Astellas fails in bid to continue US patent case against generic drug manufacturers over Myrbetriq

By Nick Robertson ( October 22, 2024, 10:54 GMT | Insight) -- A US district court ruled that Astellas Pharmaceutical cann't supplement its Abbreviated New Drug Application complaint against generic drug manufacturers with traditional patent infringement claims, after generic manufacturers released their allegedly infringing drugs onto the market.A US federal court rejected an attempt by Astellas Pharmaceuticals today to supplement its Abbreviated New Drug Application (ANDA) complaint against generic drug manufacturers with a traditional patent infringement case, after a lower court invalidated its patent and that ruling was later overturned....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections